Imatinib Attenuates IL-1β-Induced Astrocyte Inflammatory Responses and Is Associated with Reduced NF-κB and p38 MAPK Activation: Evidence Supporting Repurposing of Tyrosine Kinase Inhibitors for Neuroinflammatory Disorders
Astrocytes play a central role in the initiation and propagation of neuroinflammatory responses involved in neurodegenerative disorders, ischemic brain injury, and cancer therapy-related cognitive impairment. Increasing evidence suggests that tyrosine kinase inhibitors (TKIs) targeting BCR-ABL/PDGFR pathway, originally developed for chronic myeloid leukemia, may exert neuroprotective effects through modulation of inflammatory signaling pathways. However, the direct effects of Imatinib on activated astrocytes remain poorly characterized. In our study, human astrocytes were stimulated with IL-1β and treated with increasing concentrations of Imatinib. After 24 h, mRNA and protein levels of the inflammatory mediators IL-6, CCL2, CXCL10, MMP-9 were assayed by qPCR and ELISA. The activation of NF-κB and p38 MAPK signaling pathways were also evaluated by using ELISA and western blot, respectively.Cell viability was determined by MTT assay. IL-1β induced a marked inflammatory phenotype characterized by increased secretion of IL-6, CCL2, CXCL10, and MMP-9 together with activation of NF-κB and p38 MAPK pathways. Imatinib significantly attenuated these responses in a dose-dependent manner without impairing cell viability. Treatment reduced inflammatory mediator production and suppressed both NF-κB and p38 MAPK activation. These findings indicate that Imatinib directly modulates astrocyte inflammatory responses. Imatinib exerts potent anti-inflammatory effects in activated astrocytes. These anti-inflammatory effects were associated with reduced NF-κB and p38 MAPK activation. These findings support the growing evidence that BCR-ABL/PDGFR-targeting TKIs may have therapeutic value beyond hematological malignancies and could represent promising candidates for the treatment of neuroinflammatory and neurodegenerative disorders.
Authors
- Alessandro Allegra (ORCID: https://orcid.org/0000-0001-6156-8239)
- Letteria Minutoli (ORCID: https://orcid.org/0000-0002-8422-9667)
- Manlio Fazio (ORCID: https://orcid.org/0000-0001-8804-2640)
- Herbert Ryan Marini (ORCID: https://orcid.org/0000-0002-8254-177X)
- Stefania Stella (ORCID: https://orcid.org/0000-0002-7189-2312)
- Fabio Stagno (ORCID: https://orcid.org/0000-0002-7947-158X)
- Federica Aliquò (ORCID: https://orcid.org/0000-0003-0537-2607)
- Angela D’Ascola (ORCID: https://orcid.org/0000-0001-7530-1316)
- Adele Bottaro
Institutions
- University of Messina (IT)
- Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-10826261/v1
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- preprint